Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 6/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.30 |
| ▸ | CES2 | O00748 | 3/20 | 0.30 |
| ▸ | CES1 | P23141 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899087 | 0.90 | DNM1 (0.46) | DNM1LMNADGKA | |
| SCHEMBL9898055 | 0.86 | DNM1 (0.36) | DNM1DGKAACHEPAOXESR1 | |
| SCHEMBL30205650 | 0.84 | LMNA (0.45) | LMNADGKAESR1CES2CES1 | |
| SCHEMBL30205788 | 0.84 | LMNA (0.45) | LMNADGKAESR1CES2CES1 | |
| SCHEMBL30205659 | 0.84 | LMNA (0.45) | LMNADGKAESR1CES2CES1 | |
| SCHEMBL96679 | 0.84 | LMNA (0.45) | LMNADGKAESR1CES2CES1 | |
| SCHEMBL21049772 | 0.84 | LMNA (0.45) | LMNADGKAESR1CES2CES1 | |
| SCHEMBL97747 | 0.84 | LMNA (0.45) | LMNADGKAESR1CES2CES1 | |
| SCHEMBL21049771 | 0.84 | LMNA (0.45) | LMNADGKAESR1CES2CES1 | |
| SCHEMBL30205784 | 0.84 | LMNA (0.45) | LMNADGKAESR1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471798-B1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | BRIDGESTONE CORP (JP) | 2015-08-19 | — | — | EP | claimed |
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | US | claimed |
| US-9150595-B2 | Process for producing silane coupling agent | BRIDGESTONE CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | HAO2, SAMM50, SKP2 | DNM1 1241/4885LMNA 3112/4885DGKA 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.